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Abstract
Background
Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-
piperaquine (IPTp-DP) has been shown to reduce the burden of malaria during pregnancy
compared to sulfadoxine-pyrimethamine (IPTp-SP). However, limited data exist on how
IPTp regimens impact malaria risk during infancy. We conducted a double-blinded random-
ized controlled trial (RCT) to test the hypothesis that children born to mothers given IPTp-
DP would have a lower incidence of malaria during infancy compared to children born to
mothers who received IPTp-SP.
Methods and findings
We compared malaria metrics among children in Tororo, Uganda, born to women random-
ized to IPTp-SP given every 8 weeks (SP8w, n = 100), IPTp-DP every 8 weeks (DP8w, n =
44), or IPTp-DP every 4 weeks (DP4w, n = 47). After birth, children were given chemopre-
vention with DP every 12 weeks from 8 weeks to 2 years of age. The primary outcome was
incidence of malaria during the first 2 years of life. Secondary outcomes included time to
malaria from birth and time to parasitemia following each dose of DP given during infancy.
Results are reported after adjustment for clustering (twin gestation) and potential
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confounders (maternal age, gravidity, and maternal parasitemia status at enrolment).The
study took place between June 2014 and May 2017. Compared to children whose mothers
were randomized to IPTp-SP8w (0.24 episodes per person year [PPY]), the incidence of
malaria was higher in children born to mothers who received IPTp-DP4w (0.42 episodes
PPY, adjusted incidence rate ratio [aIRR] 1.92; 95% CI 1.00–3.65, p = 0.049) and nonsignifi-
cantly higher in children born to mothers who received IPT-DP8w (0.30 episodes PPY,
aIRR 1.44; 95% CI 0.68–3.05, p = 0.34). However, these associations were modified by
infant sex. Female children whose mothers were randomized to IPTp-DP4w had an appar-
ently 4-fold higher incidence of malaria compared to female children whose mothers were
randomized to IPTp-SP8w (0.65 versus 0.20 episodes PPY, aIRR 4.39, 95% CI 1.87–10.3,
p = 0.001), but no significant association was observed in male children (0.20 versus 0.28
episodes PPY, aIRR 0.66, 95% CI 0.25–1.75, p = 0.42). Nonsignificant increases in malaria
incidence were observed among female, but not male, children born to mothers who
received DP8w versus SP8w. In exploratory analyses, levels of malaria-specific antibodies
in cord blood were similar between IPTp groups and sex. However, female children whose
mothers were randomized to IPTp-DP4w had lower mean piperaquine (PQ) levels during
infancy compared to female children whose mothers received IPTp-SP8w (coef 0.81, 95%
CI 0.65–1.00, p = 0.048) and male children whose mothers received IPTp-DP4w (coef 0.72,
95% CI 0.57–0.91, p = 0.006). There were no significant sex-specific differences in PQ lev-
els among children whose mothers were randomized to IPTp-SP8w or IPTp-DP8w. The
main limitations were small sample size and childhood provision of DP every 12 weeks in
infancy.
Conclusions
Contrary to our hypothesis, preventing malaria in pregnancy with IPTp-DP in the context of
chemoprevention with DP during infancy does not lead to a reduced incidence of malaria in
childhood; in this setting, it may be associated with an increased incidence of malaria in
females. Future studies are needed to better understand the biological mechanisms of in
utero drug exposure on drug metabolism and how this may affect the dosing of antimalarial
drugs for treatment and prevention during infancy.
Trial registration
ClinicalTrials.gov number NCT02163447.
Author summary
Why was this study done?
• Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisi-
nin-piperaquine (DP) has been shown to reduce the burden of malaria during preg-
nancy compared to the current standard of care, sulfadoxine-pyrimethamine (SP).
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• However, although there is some evidence that malaria in pregnancy may alter malaria
susceptibility in infants, limited data exist on the impact of different IPTp regimens on
malaria during early childhood.
• We hypothesized that children born to mothers who received IPTp with DP would have
a lower incidence of malaria during the first 2 years of life compared to children born to
mothers who received IPTp with SP.
What did the researchers do and find?
• We conducted a double-blinded randomized controlled trial between June 2014 and
May 2017 comparing malaria metrics among 191 infants born to mothers randomized
to receive IPTp with SP or IPTp with DP; children born to these mothers were given
chemoprevention with DP every 12 weeks starting at 8 weeks of age and followed to 2
years of age.
• We found that children born to mothers given IPTp with DP did not have a lower inci-
dence of malaria in infancy; in fact, children born to mothers who received IPTp with
DP every 4 weeks in pregnancy had a significantly higher incidence of malaria and Plas-
modium falciparum infection in infancy.
• We found that this increased incidence of malaria was only observed in female infants;
furthermore, female children born to mothers who received IPTp with DP every 4
weeks in pregnancy had significantly lower piperaquine drug levels during infancy com-
pared to male children.
What do these findings mean?
• Although IPTp with DP is more effective in preventing malaria in pregnancy compared
to IPTp with SP, in this setting it was not associated with a lower risk of malaria in
infancy.
• Although the results show an increased risk of malaria in female infants, these results
should be interpreted with caution given the small sample size, especially when consid-
ering sex-stratified results.
• Future studies are needed both to confirm the impact of different IPTp regimens on
malaria risk in infants, including those in settings where children are not given intermit-
tent chemoprevention in infancy, as well as to understand the biologic mechanisms by
which in utero drug exposure may lead to sex-specific changes in drug metabolism.
Introduction
Malaria during pregnancy remains a significant cause of morbidity and mortality in sub-Saha-
ran Africa [1]. Although the majority of women living in endemic areas remain asymptomatic
when infected with malaria parasites, these infections are associated with maternal anemia and
adverse birth outcomes, including miscarriage, stillbirth, preterm birth, low birth weight
(LBW), and infant mortality [2]. For pregnant women living in malaria-endemic areas, WHO
Impact of IPTp-DP on risk of malaria in early childhood
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recommends the use of long-lasting insecticidal nets (LLINs) and intermittent preventive
treatment of malaria during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) to pre-
vent infection with malaria parasites and reduce the risk of adverse birth outcomes. However,
there is concern for diminishing efficacy of these interventions because of the spread of vector
resistance to the pyrethroid insecticides used in LLINs and widespread parasite resistance to
SP [3,4]. Dihydroartemisinin-piperaquine (DP) has emerged as an attractive alternative to SP
for IPTp, as it is highly efficacious and provides at least 4 weeks of posttreatment prophylaxis
[5,6]. Recent randomized controlled trials (RCTs) from our group and others showed that,
compared to IPTp-SP, IPTp-DP dramatically reduced risks of maternal parasitemia, symp-
tomatic malaria, anemia, and placental malaria, and IPTp-DP was as safe and well tolerated as
IPTp-SP [7,8]. However, there were minimal differences between the SP and DP groups in
risks of adverse birth outcomes, including LBW and preterm birth. Furthermore, it remains
unclear what impact these different IPTp regimens have on the risk of malaria during early
childhood.
Several studies have reported associations between malaria in pregnancy and a child’s sub-
sequent risk of malaria, with mixed findings. Many have reported that infants born to mothers
with placental malaria [9–14] or peripheral parasitemia during pregnancy [15] have a signifi-
cantly higher risk of malaria during infancy. However, one study found a lower risk of malaria
in infancy among infants born to primigravid mothers with placental malaria than infants
born to primigravid mothers without placental malaria [14], and others have reported no sig-
nificant association between malaria in pregnancy and the risk of malaria in infancy [16–18].
Notably, all of these studies were observational and any associations observed were subject to
confounding by shared levels of exposure to malaria-infected mosquitoes between mothers
and their infants [16,19].
If malaria in pregnancy alters a child’s subsequent risk of malaria, one would hypothesize
that maternal receipt of effective IPTp might alter this risk, although few studies have exam-
ined this question with rigorous randomized controlled studies. In an older, placebo-con-
trolled trial of IPTp with mefloquine in Thailand, infants followed after birth whose mothers
had either received mefloquine or placebo had similar risks of Plasmodium falciparum infec-
tion and symptomatic disease [20]. Three more recent IPTp trials in Africa comparing IPTp-
SP + LLIN with LLIN alone [12], IPTp-SP with mefloquine [21], or IPTp-SP with intermittent
screening and treatment (IST) with artemether-lumefantrine (AL) [18] also found that the
incidence of malaria from birth to 12 months of age was not significantly different between
groups of children. However, in each of these studies, the experimental IPTp group was not
shown to significantly reduce the burden of placental malaria compared to controls [22–24].
We conducted a double-blinded RCT to evaluate the impact of different IPTp regimens on
the risk of malaria in infancy. Pregnant women were randomized to receive IPTp with SP
every 8 weeks (IPTp-SP8w), IPTp with DP every 8 weeks (IPTp-DP8wk), or IPTp with DP
every 4 weeks (IPTp-DP4w). Children born to these mothers were given chemoprevention
with DP every 12 weeks starting at 8 weeks of age and followed to 2 years of age. We tested the
hypothesis that children born to mothers who received IPTp with DP would have a lower inci-
dence of malaria during the first 2 years of life compared to children born to mothers who
received IPTp with SP.
Methods
Ethics statement
The study was funded by the National Institutes of Health and approved by the Institutional
Review Boards of the Makerere University School of Biomedical Sciences, the Uganda
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National Council for Science and Technology, and the University of California, San Francisco.
Written informed consent was obtained from all study participants.
Study setting and participants
The study was conducted in Tororo district, Uganda, from June 2014 through May 2017. Tor-
oro district is an area of historically high malaria transmission intensity with perennial trans-
mission and an estimated entomologic inoculation rate of 310 infectious bites per person-year
in 2013 [25]. Following a universal LLIN campaign in November 2013, near universal LLIN
coverage was reported in Tororo district, with minimal change in malaria metrics after LLIN
distribution [26]. From December 2014 to February 2015, indoor residual spraying (IRS)
using the carbamate bendiocarb was initiated in Tororo district for the first time and was asso-
ciated with significant reductions in malaria transmission [26,27]; a second round of bendio-
carb was conducted in June–July 2015, and a third round in November–December 2015. A
fourth round of IRS was conducted in June–July 2016 with pyrimiphos-methyl (Actellic), a
long-lasting organophosphate.
This study was divided into 2 phases, the first phase randomizing pregnant women to dif-
ferent IPTp regimens and the second phase—the focus of this analysis—following children
born from these mothers to 2 years of age. In the first phase of this study, pregnant women
were screened and enrolled between June 2014 and October 2014. Eligible mothers were not
infected with HIV and were of all gravidities, with an estimated gestational age between 12 and
20 weeks, confirmed by ultrasound, and provided written informed consent. Complete entry
criteria are provided (see S1 Study Protocol) and have been previously described [28]. In the
second phase of this study, children were born between October 2014 and May 2015 and fol-
lowed through 2 years of age, with the last participant followed through May 2017.
Study design and randomization
This was a double-blinded RCT of pregnant women not infected with HIV and the children
born to them. Women and their unborn child(ren) were randomized to one of five treatment
arms, including both the intervention for the woman during pregnancy and her unborn child
(ren) during infancy, in a 2:1:1:1:1 randomization scheme, as follows: (1) women IPTp-SP8w,
children DP every 12 weeks; (2) women IPTp-DP8w, children DP every 12 weeks; (3) women
IPTp-DP8w, children DP every 4 weeks; (4) women IPTp-DP4w, children DP every 12 weeks;
and (5) women IPTp-DP4w, children DP every 4 weeks. To compare the malaria risk among
infants whose mothers were randomized to different IPTp regimens, the prespecified proto-
col-defined study population included only mother/infant pairs in one of the three study arms
randomized to receive DP every 12 weeks during infancy, because we hypothesized that chil-
dren randomized to receive DP every 4 weeks in infancy would be nearly completely protected
against malaria in infancy [29].
A randomization list using permuted blocks of 6 or 12 was computer generated by a mem-
ber of the study not directly involved in patient care. Study participants were randomized to
their assigned treatment group at enrolment using premade, consecutively numbered, sealed
envelopes. Non-singleton births from the same mother were assigned to the same intervention.
Study pharmacists not otherwise involved in the study were responsible for treatment alloca-
tion and the preparation of study drugs.
Study drugs
In pregnancy, each treatment with SP (Kamsidar, Kampala Pharmaceutical Industries, 500/25
mg tablets) consisted of 3 tablets given as a single dose. Each treatment with DP in pregnancy
Impact of IPTp-DP on risk of malaria in early childhood
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(Duo-Cotexin, Holley-Cotec, Beijing, China, 40 mg/320 mg tablets) consisted of 3 tablets
given once a day for 3 consecutive days. Participants allocated IPTp-SP8w or IPTp-DP8w
received active study drugs at 20, 28, and 36 weeks gestational age. Participants allocated IPTp-
DP4w received active study drugs starting at 16 or 20 weeks gestational age. Placebos of SP and
DP were used such that every 4 weeks participants received the same number of pills, with the
same appearance.
Each treatment with DP in childhood consisted of half-strength tablets given once a day for
3 consecutive days (Duo-Cotexin, Holley-Cotec, Beijing, China, 20 mg/160 mg tablets),
according to weight-based guidelines (see S1 Study Protocol). Infants randomized to receive
DP every 12 weeks received placebo mimicking the dosing of DP every 4 weeks when they
were not receiving study drug. The first day of each dose was directly observed in the clinic by
study nurses, who had the flexibility to administer either intact or crushed tablets to the
infants. Compliance with day 2 and day 3 dosing administered at home was assessed at the fol-
lowing monthly routine visit and was reported to be>99%.
Study procedures
At enrolment, women received an LLIN and underwent a standardized examination. Pregnant
women and their children received all of their medical care at a study clinic open every day.
Study procedures for pregnant women have previously been described, with details available
in S1 Study Protocol [8]. Briefly, during pregnancy, routine visits were conducted every 4
weeks, including collection of dried blood spots (DBS) for molecular testing, and women were
encouraged to deliver at the hospital adjacent to the study clinic. At delivery, a standardized
assessment was completed, including evaluation of birth weight and collection of biological
specimens, including maternal blood, placental tissue, placental blood, and cord blood.
Following delivery, children were followed through 24 months of age and encouraged to
come to the study clinic any time they were ill. Those who presented with a documented fever
(tympanic temperature38.0 ˚C) or history of fever in the previous 24 hours had blood col-
lected for a thick blood smear. If the smear was positive, the patient was diagnosed with
malaria and treated with AL. If the thick blood smear was negative, the patient was managed
for a non-malarial febrile illness by study physicians. Episodes of uncomplicated malaria in
children <4 months of age or weighing <5 kg, as well as episodes of complicated malaria and
treatment failures within 14 days, were treated with either quinine or artesunate according to
national malaria treatment guidelines. Routine visits were conducted every 4 weeks in chil-
dren, including thick blood smears to assess for parasitemia by microscopy, collection of DBS
for molecular testing, and collection of plasma by fingerprick for assessment of piperaquine
(PQ) levels. Phlebotomy for routine laboratory tests, including complete blood count (CBC),
was performed every 16 weeks. Adverse events were assessed and graded according to stan-
dardized criteria at every visit to the study clinic [30].
Clinical laboratory procedures
Blood smears were stained with 2% Giemsa and read by experienced laboratory technologists.
A blood smear was considered negative when the examination of 100 high-power fields did
not reveal asexual parasites. For quality control, all slides were read by a second microscopist,
and a third reviewer would settle any discrepant readings. DBS were tested for the presence of
malaria parasites using a loop-mediated isothermal amplification (LAMP) kit (Eiken Chemi-
cal, Japan).
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Antibody measurements
IgG responses to 19 parasite surface antigens were measured in maternal and cord blood col-
lected at delivery, including circumsporozoite protein (CSP), erythrocyte binding antigen
(EBA) 140 region III-V (RIII-V), EBA175 RIII-V [31,32], EBA181 RIII-V, Early transcribed
membrane protein (Etramp) 4, Etramp 5, gametocyte exported protein (GEXP18), H103/mer-
ozoite surface protein (MSP) 11, Heat shock protein 40 (HSP40), Plasmodium exported pro-
tein (Hyp2) [33]), MSP 2 (Ch150/9 and Dd2 alleles) [34], Apical membrane antigen 1 (AMA1)
[31,32,35], glutamate rich protein (GLURP-R2)[36], MSP1-19 [31,32,37], Schizont egress anti-
gen (SEA)-1 [38], Reticulocyte-binding protein homologue (Rh)2_2030, Rh4.2, and skeleton-
binding protein 1 (SBP1). Glutathione S-transferase (GST) and Tetanus toxoid were used as
controls. Luminex magnetic microsphere conjugation was performed by standard methods
[39]. Fifty microliters thawed plasma (1/1,000 dilution) were coincubated with microsphere
mixtures on a 96-well plate for 90 minutes, washed, then stained with 50 uL of 1/200 R-Phyco-
erythrin-conjugated AffiniPure F(ab’)2 Goat anti-human IgG (Jackson Immuno Research
Laboratories) secondary antibody. Samples were then suspended in 100 uL PBS and read by
the Luminex MAGPIX system. Positive control samples from individuals (n = 20) with known
antibodies to these antigens were included on each plate. Standard curves were generated
through serial dilutions of the positive control pool. Antibody levels, expressed in arbitrary
units (AUs), were obtained by regressing raw MFI onto the standard curve for each antigen
present on every plate and results log transformed [40].
PQ pharmacokinetic sample collection and quantitation
Children provided capillary blood samples at 3 consecutive routine visits performed every 4
weeks after they received the 8, 32, 56, and 92 week doses of DP in infancy.
Pharmacokinetic samples (n = 1,505) were centrifuged within 60 minutes at 2,000g for 10
minutes, and plasma was stored at −80˚C prior to being processed for PQ quantitation. PQ
concentrations were determined using high performance liquid chromatography tandem mass
spectrometry, as described [41], with modifications to lower the calibration range to 0.5–50
ng/mL and a new calibration range of 10–1,000 ng/mL. The lower limit of quantification
(LLOQ) was 0.5 ng/mL and the coefficient of variance was<10% for all quality control
concentrations.
Study end points
The primary outcome was the incidence of malaria from birth to 24 months of age. Treatments
for malaria within 14 days of a prior episode were not considered incident events. Secondary
outcomes included time to malaria from birth and time to parasitemia following receipt of
each dose of DP; the incidence of complicated malaria; the incidence of hospitalizations/
deaths; the incidence of non-malarial febrile illness (presentation within 14 days of a prior epi-
sode were not considered incident events); and the prevalence of anemia (Hb< 11 g/dL) dur-
ing infancy. Measures of safety included the incidence of adverse events from birth through 2
years of age. Post hoc, exploratory outcomes included the relative intensity of malarial anti-
bodies measured at delivery (maternal and cord); and PQ levels measured 4, 8, and 12 weeks
following receipt of DP. The primary exposure variable was maternal IPTp assignment.
Statistical analysis
To test the hypothesis that either IPTp-DP4w or IPTP-DP8w would be associated with a lower
risk of malaria in infancy compared to SP, we assumed an incidence of malaria of 3–5 episodes
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per person year (PPY) among children whose mothers were randomized to IPTp-SP8w based
on prior data before the implementation of IRS. Assuming 5% lost to follow-up, we had 80%
power to show a 22%–28% reduction in the incidence of malaria among infants whose moth-
ers were randomized to either IPTp-DP4w or IPTp-DP8w (2-sided significance level = 0.05).
Data were double-entered and verified in Microsoft Access and statistical analysis per-
formed using Stata, version 14. All analyses were done using a modified intention-to-treat
approach, including all children born (excluding stillbirths) and randomized to DP every 12
weeks with evaluable person-time of follow-up. Any premature withdrawal from the study
prior to 2 years of age was assumed to be random. Comparisons of simple proportions were
made using the chi-squared or Fisher’s exact test. Comparisons of incidence measures were
made using a negative binomial regression model. We assessed for significant interaction
(p< 0.10) with the primary outcome and the following potential effect modifiers: sex of the
infant, gestational age of the infant at birth, and maternal gravidity. Where significant effect
modification was noted, results were reported from stratified analysis. The cumulative risk of
developing malaria from birth was estimated using the Kaplan–Meier product limit formula,
and associations with exposure variables assessed using a cox proportional hazards model. The
cumulative risk of developing malaria parasitemia following receipt of each dose of DP in
infancy was estimated using a multilevel mixed-effects parametric survival model, accounting
for clustering within individuals and mothers (twin gestation). Comparisons of proportions
with repeated measures were made using mixed effects logistic regression models. In all analy-
ses, estimates accounted for maternal clustering (twin gestation). Estimates were adjusted for
potential confounders (maternal age, gravidity, and maternal parasitemia status at enrolment);
both unadjusted and adjusted results were reported in tables; adjusted estimates are presented
in the text.
In post hoc analyses, comparisons of log-transformed antibody levels between groups were
performed using the student t test. For PQ measurements, relationships between mean popula-
tion PQ concentrations, days since dosing, maternal randomization, and infant sex were
assessed using generalized estimating equations with log link and robust standard errors
accounting for repeated observations within individuals. Marginal estimates were produced
using final models and shown graphically. In all analyses, p< 0.05 was considered statistically
significant, without adjustment for multiple comparisons.
Results
Study participants and follow-up
Between June 2014 and October 2014, 386 pregnant women not infected with HIV and their
unborn children were screened, and 300 were enrolled and randomized to one of five treat-
ment arms defined by both maternal IPTp (SP8w, DP8w, or DP4w) and infant intermittent
preventive treatment (IPT) (DP every 4 or 12 weeks beginning at 8 weeks of age, Fig 1).
Among pregnant women/child pairs enrolled, 202 were randomized to receive DP every 12
weeks in infancy and included in this analysis. Of these, 106 women were randomized to
IPTp-SP8w; 46 to IPTp-DP8w, and 50 to IPTp-DP4w. A total of 192 women (95.0%) were fol-
lowed through delivery, and 4 women gave birth to twins. Of 194 live births, 191 children were
followed for at least one day and included in the analyses. All children were born between
October 2014 and May 2015.
Mean maternal age at enrolment was 22 years, 69% of women were enrolled at16 weeks
gestational age, 37% were primigravida, and 57% had malaria parasites detected by LAMP.
Baseline maternal characteristics were not significantly different between the 3 IPTp arms,
except for age, with women randomized to IPTp-SP8w slightly younger than women
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randomized to the other 2 treatment groups (Table 1). After initiation of IPTp, the incidence
of malaria was significantly higher during pregnancy in mothers who received IPTp-SP8w
(0.95 episodes PPY) compared to mothers who received IPTp-DP8w (0.23 episodes PPY,
p = 0.004) or IPTp-DP4w (0 episodes PPY, p< 0.001). Similarly, parasite prevalence during
pregnancy was significantly higher in mothers who received IPTp-SP8w compared to mothers
who received IPTp-DP8w or IPTp-DP4w. The prevalence of placental malaria determined by
Fig 1. Trial profile. DP, dihydroartemisinin-piperaquine; IPTp-DP4w, IPTp-DP every 4 weeks; IPTp-DP8w, IPTp-DP given every 8 weeks; IPTp-
SP8w, IPTp-SP given every 8 weeks.
https://doi.org/10.1371/journal.pmed.1002606.g001
Table 1. Characteristics of mother-child pairs stratified by mother’s IPTp treatment arm.
Characteristic Mother’s IPTp treatment arm
SP8w (n = 100) DP8w (n = 44) DP4w (n = 47)
Characteristics of mothers at enrolment
Age in years, mean (SD) 21.4 (3.6) 23.0 (4.1) 23.0 (3.8)
Weeks of gestation, n (%)
12–16 weeks 71 (71.0%) 29 (65.9%) 31 (66.0%)
>16–20 weeks 29 (29.0%) 15 (34.1%) 16 (34.0%)
Mother’s gravidity, n (%)
1 35 (35.0%) 10 (22.7%) 10 (21.3%)
2 33 (33.0%) 16 (36.4%) 16 (34.0%)
3 32 (32.0%) 18 (40.9%) 21 (44.7%)
Household wealth index, n (%)
Lowest third 37 (37.0%) 11 (25.0%) 15 (31.9%)
Middle third 29 (29.0%) 19 (43.2%) 15 (31.9%)
Highest third 34 (34.0%) 14 (31.8%) 17 (36.2%)
Detection of malaria parasites by LAMPa, n (%) 56 (56.0%) 19 (43.2%) 27 (57.5%)
Characteristics of mothers during pregnancy after initiation of study drugs
p-value p-value
Incidence of malariab 0.95 0.23 0.004 0 <0.001
Parasite prevalencec 201/499 (40.3%) 24/203 (11.8%) <0.001 8/239 (3.4%) <0.001
Placental malaria by microscopy, n/N (%) 4/96 (4.2%) 1/44 (2.3%) 0.58 0/45 (0%) 0.17
Placental malaria by LAMPa, n/N (%) 19/96 (19.8%) 1/44 (2.3%) 0.006 0/45 (0%) 0.001
Placental malaria by histology, n/N (%) 49/97 (50.5%) 13/44 (29.6%) 0.02 10/45 (22.2%) 0.001
Characteristics of children at birth
p-value p-value
Female sex, n (%) 51 (51.0%) 24 (54.6%) 0.70 23 (48.9%) 0.82
Gestational age in weeks at birth, mean (SD) 39.3 (1.8) 39.1 (2.6) 0.54 40.0 (1.2) 0.03
Preterm births (<37 weeks of gestation), n (%) 8 (8.0%) 5 (11.4%) 0.52 1 (2.1%) 0.17
Birth weight in grams, mean (SD) 2,967 (447) 2,928 (532) 0.65 3,024 (339) 0.44
Low birth weight (<2,500 gm), n (%) 13 (13.0%) 6 (13.6%) 0.92 2 (4.3%) 0.10
Reference group.
aLoop amplified isothermal amplification.
bEpisodes of malaria per person year at risk.
cProportion of routine blood samples positive for malaria parasites by LAMP.
Abbreviations: DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given every 8 weeks; IPTp, intermittent preventive treatment of malaria in pregnancy; LAMP, loop-
mediated isothermal amplification; SP8w, IPTp-SP given every 8 weeks.
https://doi.org/10.1371/journal.pmed.1002606.t001
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LAMP or histopathology was significantly higher among women who received IPTp-SP8w
compared to women who received IPTp with either IPTp-DP8w or IPTp-DP4w (Table 1).
Of 191 children born and followed, 98 (51.3%) were female, 14 (7.3%) were born preterm,
and 21 (11%) were born with LBW (<2,500 g), and these characteristics were not significantly
different based on maternal IPTp. Median gestation age at birth was slightly older for babies
born to mothers who received IPTp-DP4w (median gestation age 40 weeks [35.7–41.6 weeks])
compared to those born to mothers who children whose mothers received IPTp-SP8w
(median gestation age 39.3 weeks [31.7–42.0 weeks], p = 0.03, Table 1). Of 191 children fol-
lowed, 164 (86%) completed follow-up through 2 years of age (Fig 1). When considering per-
son-time of follow-up, 355.1 of 382 (93%) possible person years were observed.
Impact of IPTp with DP on burden of malaria in infancy
During 355.1 person years of follow-up, there were 105 incident episodes of malaria in infants,
giving an overall incidence of 0.30 episodes PPY. Compared to children born to mothers who
received IPTp-SP8w, the incidence of malaria during 24 months of follow-up was higher in
children born to mothers who received IPTp-DP4w (adjusted incidence rate ratio [aIRR] 1.92;
95% CI 1.00–3.65, p = 0.049) and nonsignificantly higher in children born to mothers who
received IPT-DP8w (aIRR 1.44; 95% CI, 0.68–3.05; p = 0.34, Table 2). However, we observed
significant effect modification by infant sex. Female children born to mothers who received
IPTp-DP4w had a greater than 4-fold apparently higher incidence of malaria (aIRR 4.39; 95%
CI, 1.87–10.3; p = 0.001) compared to female children born to mothers who received IPTp-
SP8w. Similarly, female children born to mothers who received IPTp-DP8w had a higher, but
nonsignificant, risk of malaria compared to female children born to mothers who received
IPTp-SP8w (aIRR 2.43; 95% CI, 0.85–6.97; p = 0.10). In contrast, there were no significant dif-
ferences in the incidence of malaria among male children across the 3 IPTp treatment arms
Table 2. Incidence of malaria though 24 months of age by mother’s IPTp treatment arm overall and stratified by infant sex.
Sex Mother’s IPTp treatment
arm
Number of
children
Episodes of
malaria
PY of
observation
Incidence of malaria
PPY
IRR (95%
CI)
p-value aIRRa (95%
CI)
p-value
Allb SP8w 100 44 185.2 0.24 reference reference
DP8w 44 25 84.2 0.30 1.29
(0.63–2.64)
0.49 1.44
(0.69–3.02)
0.33
DP4w 47 36 85.5 0.42 1.81
(0.93–3.53)
0.08 1.92
(1.00–3.65)
0.049
Female SP8w 51 18 91.3 0.20 reference reference
DP8w 24 16 44.3 0.36 1.91
(0.65–5.64)
0.24 2.43
(0.85–6.97)
0.10
DP4w 23 27 41.3 0.65 3.44
(1.41–8.40)
0.007 4.39
(1.87–10.3)
0.001
Male SP8w 49 26 94.0 0.28 reference reference
DP8w 20 9 40.0 0.23 0.82
(0.38–1.77)
0.62 0.84
(0.37–1.90)
0.67
DP4w 24 9 44.2 0.20 0.74
(0.25–2.17)
0.58 0.66
(0.25–1.75)
0.41
aAdjusted for maternal age, gravidity, LAMP status at enrolment, and maternal clustering for twin gestation.
bInteraction p-value between female sex and IPTp arm: 0.22 for ITPp-DP8w; 0.03 for IPTp-DP4w.
Abbreviations: aIRR, adjusted incidence rate ratio; DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given every 8 weeks; IPTp, intermittent preventive treatment of
malaria in pregnancy; IRR, incidence rate ratio; LAMP, loop-mediated isothermal amplification; PY, person year; PPY, person per year; SP8w, IPTp-SP given every 8
weeks.
https://doi.org/10.1371/journal.pmed.1002606.t002
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(Table 2). No significant effect modification was observed with maternal gravidity or gesta-
tional age at birth.
Children born to mothers who received IPTp-DP4w had a nonsignificantly increased haz-
ard of developing a first episode of malaria during the first 2 years of life in comparison to chil-
dren born to mothers who received IPTp-SP8w (adjusted hazard ratio [aHR] 1.76, 95% CI 0.93–
3.35, p = 0.08), but we again observed significant interaction with infant sex. Female infants
whose mothers received IPTp-DP4w had a 3-fold apparently increased hazard of developing
malaria compared to infants born to mothers who received IPTp-SP8w (aHR 3.40; 95%
CI,1.55–7.96; p = 0.002, Table 3). Female children born to mothers who received IPTp-DP8w
also had a higher, but nonsignificant, increased risk of malaria compared to those whose moth-
ers received IPTp-SP8w; no significant associations were observed among male children across
the 3 IPTp treatment arms (Table 3). These data do not support our original hypothesis that pre-
venting malaria exposure in utero with DP leads to a reduced incidence of malaria in childhood;
in contrast, in this setting it may be associated with an increased incidence of malaria in females.
Given these differences, we assessed whether the incidence of malaria was different between
male and female children. Overall, female children had a nonsignificantly increased incidence
of malaria compared to males (aIRR 1.43, 95% CI 0.82–2.50, p = 0.21), but this effect was modi-
fied by maternal IPTp. Female children whose mothers were randomized to IPTp-DP4w had a
>3-fold apparently increased risk of malaria compared to males (aIRR 3.34, 95% CI 1.08–10.26,
p = 0.04). However, there were no significant sex-specific differences among children whose
mothers were randomized to IPTp-SP8w (aIRR 0.72, 95% CI 0.31–1.67 comparing females to
males) or IPTp-DP8w (aIRR 1.66, 95% CI 0.59–4.67 comparing females to males). These data
suggest that, in this setting, female infants appear to have an increased risk of malaria in infancy
compared to males, but only among those whose mothers received IPTp-DP4w.
Table 3. Time to first episode of malaria by mother’s IPTp treatment arm overall and stratified by infant sex.
Sex Mother’s IPTp treatment
arm
Number of
children
Number with any
malaria
Cumulative risk of any malaria
(95% CI)
HR (95%
CI)
p-value aHRa (95%
CI)
p-value
Allb SP8w 100 26 28.4%
(20.2%–38.3%)
reference reference
DP8w 44 13 30.8%
(19.2%–47.1%)
1.15
(0.59–2.26)
0.68 1.36
(0.67–2.76)
0.40
DP4w 47 16 37.0%
(24.6%–53.2%)
1.54
(0.82–2.91)
0.18 1.76
(0.93–3.35)
0.08
Female SP8w 51 11 24.3%
(14.3%–39.7%)
reference reference
DP8w 24 5 22.4%
(10.0%–45.7%)
0.97
(0.33–2.83)
0.96 1.21
(0.39–3.69)
0.74
DP4w 23 11 52.4%
(33.3%–74.3%)
2.97
(1.29–6.84)
0.01 3.40
(1.55–7.96)
0.002
Male SP8w 49 15 32.3%
(20.9%–47.8%)
reference reference
DP8w 20 8 40.0%
(22.4%–64.3%)
1.35
(0.58–3.18)
0.49 1.51
(0.59–3.88)
0.39
DP4w 24 5 22.7%
(10.1%–46.3%)
0.71
(0.25–1.98)
0.51 0.82
(0.29–2.32)
0.71
aAdjusted for maternal age, gravidity, LAMP status at enrolment, and maternal clustering for twin gestation.
bInteraction p-value between female sex and IPTp arm: 0.63 for ITPp-DP8w; 0.03 for IPTp-DP4w.
Abbreviations: aHR, adjusted hazard ratio; DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given every 8 weeks; HR, hazard ratio; IPTp, intermittent preventive
treatment of malaria in pregnancy; LAMP, loop-mediated isothermal amplification; SP8w, IPTp-SP given every 8 weeks.
https://doi.org/10.1371/journal.pmed.1002606.t003
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After observing an apparently higher risk of clinical malaria among female infants whose
mothers received IPTp-DP4w compared to those whose mothers received IPTp-SP8w, we next
sought to determine whether these infants were at an increased risk of P. falciparum infection
in infancy versus an increased risk of symptoms if infected. As children followed in this study
received curative IPT with DP every 12 weeks beginning at 8 weeks of age, and had both pas-
sive and active surveillance for P. falciparum infection, we assessed time to parasitemia follow-
ing each dose of DP in infancy. Overall, children born to mothers who received IPTp-DP4w
had an increased hazard of parasitemia following receipt of DP in infancy compared to chil-
dren born to mothers who received IPTp-SP8w (aHR 2.02, 95% CI 1.08–3.79, p = 0.03, Fig 2A,
Table 4), but we again observed significant interaction with infant sex. Female infants whose
mothers had received IPTp-DP4w had a more than 5-fold apparently increased hazard of
developing parasitemia following receipt of DP in infancy than children born to mothers who
received IPTp-SP8w (aHR, 5.02; 95% CI, 1.90–13.2, p = 0.001, Fig 2B, Table 4). There was no
significant difference in the hazard of developing parasitemia among male children born to
mothers who received IPTp-DP4w or IPTp-DP8w compared to male children born to mothers
who received IPTp-SP8w (Table 4, Fig 2C). Prior to first receipt of DP at 8 weeks of age, parasi-
temia was rare: 1/182 (0.55%) were LAMP positive at week 4, and 3/183 (1.64%) were
Fig 2. Time to parasitemia following DP administration in infancy. Repeated measures analysis performed, using multilevel mixed-effects survival model, account
for clustering within individuals and mothers, both overall (A) and stratified by infant sex (B–C) and adjusted for maternal age, gravidity, and LAMP status at
enrolment. aHR and p-values comparing IPTp-DP4w versus IPTp-SP8w. aHR, adjusted hazard ratio; DP, dihydroartemisinin-piperaquine; IPTp, intermittent
preventive treatment of malaria in pregnancy; IPTp-DP4w, IPTp-DP every 4 weeks; IPTp-DP8w, IPTp-DP every 8 weeks; IPTp-SP8w, IPTp-SP given every 8 weeks;
LAMP, loop-mediated isothermal amplification.
https://doi.org/10.1371/journal.pmed.1002606.g002
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microscopy or LAMP positive at 8 weeks of age. All 4 children with parasitemia at or before 8
weeks of age were born to mothers who received IPTp-SP8w, and none of these episodes were
symptomatic. These data suggest that the increased incidence of malaria among female infants
whose mothers received IPTp-DP4w is directly related to an increased risk of blood stage
P. falciparum infection following receipt of DP in infancy.
Secondary clinical and safety outcomes
During 2 years of follow-up, there were 9 episodes of complicated malaria: 4 among the 100
infants whose mothers received IPTp-SP8w (0.02 episodes PPY), 2 among 44 infants whose
mothers received IPTp-DP8w (0.02 episodes PPY), and 3 among 47 infants whose mothers
received IPTp-DP4w (0.04 episodes PPY). The risk of complicated malaria did not signifi-
cantly differ between IPTp groups, nor between infant sex (5 episodes in males, 4 in females).
Of the 9 episodes, 8 occurred between 12 and 24 months of age, 6 of 9 represented the child’s
first episode of malaria and were associated with 1–2 convulsive episodes, and no episodes of
cerebral malaria or severe anemia were observed. There were 3 deaths among infants included
in this study. None of the deaths were due to malaria. Overall, there were 18 hospitalizations
or deaths, with no significant difference in the number of hospitalization or deaths between
IPTp treatment arms (Table 5). Children whose mothers received IPTp-DP4w or IPTp-DP8w
had a nonsignificantly lower risk of anemia (hemoglobin <11 g/dL) compared to children
whose mothers received IPTp-SP8w. Children born to mothers who received IPTp-DP4w or
IPTp-DP8w also had a nonsignificantly lower incidence of non-malarial febrile illnesses com-
pared to children born to mothers who received IPTp-SP8w (Table 5). These results are consis-
tent with one other observational birth cohort, which found that malaria in pregnancy was
associated with a higher risk of non-malarial febrile illness [42]. There were no significant
Table 4. Time to parasitemia following each dose of DP by mother’s IPTp treatment arm overall and stratified by infant sex.
Sex Mother’s IPTp
treatment arm
Number of doses
of DP
Number with any
parasitemia
Cumulative risk of any
parasitemia (95% CI)
HR (95% CI) p-value aHRa (95% CI) p-value
Allb SP8w 742 52 7.1%
(5.5%–9.3%)
reference reference
DP8w 313 25 7.5%
(5.1%–10.9%)
1.12
(0.56–2.24)
0.75 1.28
(0.64–2.60)
0.49
DP4w 300 43 12.8% (9.6%–16.8%) 2.02
(1.08–3.79)
0.03 2.16
(1.14–4.11)
0.02
Female SP8w 365 21 5.9%
(3.9%–9.0%)
reference reference
DP8w 178 15 8.6%
(5.3%–13.9%)
1.61
(0.58–4.47)
0.36 2.28
(0.78–6.63)
0.13
DP4w 165 29 17.9%
(12.8%–24.7%)
4.18
(1.64–10.7)
0.003 5.02
(1.90–13.2)
0.001
Male SP8w 377 31 8.4%
(6.0%–11.7%)
reference reference
DP8w 160 10 6.3%
(3.5%–11.4%)
0.77
(0.31–1.92)
0.58 0.72
(0.28–1.80)
0.48
DP4w 178 14 8.0%
(4.8%–11.2%)
0.95
(0.41–2.20)
0.91 0.91
(0.39–2.10)
0.83
aAdjusted for maternal age, gravidity, LAMP status at enrolment, and maternal clustering for twin gestation.
bInteraction p-value between female sex and IPTp arm: 0.31 for ITPp-DP8w; 0.02 for IPTp-DP4w.
Abbreviations: aHR, adjusted hazard ratio; DP, dihydroartemisinin-piperaquine; DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given every 8 weeks; HR, hazard ratio;
IPTp, intermittent preventive treatment of malaria in pregnancy; LAMP, loop-mediated isothermal amplification; SP8w, IPTp-SP given every 8 weeks.
https://doi.org/10.1371/journal.pmed.1002606.t004
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differences in the incidence of adverse events of any severity, grade 3–4 adverse events, or seri-
ous adverse events (S1 Table). No adverse events were thought to be related to study drugs.
Impact of IPTp with DP on antibody responses in infancy
Given the apparent sex-specific differences in malaria risk observed among infants whose mothers
were randomized to different IPTp regimens, we then performed exploratory analyses to evaluate
potential mechanistic explanations. As passive transfer of protective antibodies from the mother
to the newborn may lead to a reduced risk of malaria early in life [37,43], we first assessed the
impact of maternal IPTp regimens on malaria-specific IgG antibody levels in maternal and infant
cord blood using a high-sensitivity Luminex-based, multiplex fluorescent bead-based assay.
Although antibody levels to several antigens were significantly lower at delivery among mothers
who received IPTp-DP4w in comparison to mothers who received IPTp-SP, IgG antibody levels
measured in infant cord blood were similar between groups for all antigens (Fig 3). Furthermore,
no significant sex-specific differences in antibody levels were observed. Therefore, the increased
malaria risk observed among female infants whose mothers received IPTp-DP4w did not appear
to be due to decreased malaria-specific antibody levels secondary to suppression of infection.
Exposure to DP during pregnancy and PQ levels in infancy
Because PQ trough levels are strongly predictive of malaria risk among children receiving IPT
with DP [29], we next assessed whether there were sex-specific differences in PQ levels in
infancy and whether in utero exposure to DP alters these PQ levels. Capillary PQ levels were
measured 28, 56, and 84 days post the 8, 32, 56, and 92 week doses of DP in infancy (n = 1,505
measurements). Female children whose mothers were randomized to IPTp-DP4w had 19%
lower mean PQ levels during infancy compared to female children whose mothers received
IPTp-SP8w (coef 0.81, 95% CI 0.65–1.00, p = 0.048). In contrast, male children whose mothers
Table 5. Secondary outcomes by mother’s IPTp regimen.
Outcome Sex Mother’s IPTp
treatment arm
Episodes or
prevalence
PY of
observation
Incidence
PPY
IRR or OR
(95% CI)
p-
value
aIRRa or aORa
(95% CI)
p-
value
Hospitalizations or
deaths
All SP8w 9 185.2 0.05 reference reference
DP8w 2 84.2 0.02 0.49
(0.11–2.18)
0.35 0.52
(0.11–2.47)
0.41
DP4w 7 85.5 0.08 1.69
(0.43–4.42)
0.29 1.76
(0.64–4.90)
0.28
Non-malarial febrile
illnesses
All SP8w 769 185.2 4.15 reference reference
DP8w 302 84.2 3.59 0.85
(0.69–1.06)
0.16 0.86
(0.69–1.07)
0.17
DP4w 292 85.5 3.42 0.82
(0.67–1.02)
0.07 0.82
(0.66–1.02)
0.08
Anemiab All SP8w 295/619 (47.7%) reference reference
DP8w 126/279 (45.2%) 0.85
(0.51–1.44)
0.55 0.91
(0.54–1.54)
0.73
DP4w 119/285 (41.8%) 0.73
(0.44–1.22)
0.24 0.78
(0.46–1.29)
0.33
aAdjusted for maternal age, gravidity, LAMP status at enrolment, and maternal clustering for twin gestation.
bHemoglobin <11 gm/dL at the time of routine visits conducted every 16 weeks.
Abbreviations: aIRR, adjusted incidence rate ratio; aOR, adjusted odds ratio (for anemia prevalence models); DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given
every 8 weeks; IPTp, intermittent preventive treatment of malaria in pregnancy; IRR, incidence rate ratio; LAMP, loop-mediated isothermal amplification; OR, odds
ratio; PY, person year; PPY, per person year; SP8w, IPTp-SP given every 8 weeks.
https://doi.org/10.1371/journal.pmed.1002606.t005
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were randomized to IPTp-DP4w had 17% higher mean PQ levels during infancy compared to
males whose mothers received IPTp-SP8w, although not significantly so (coef 1.17, 95% CI
0.92–1.50, p = 0.21). In addition, female children whose mothers were randomized to IPTp-
DP4w had 28% lower mean PQ levels post-dose than male children (coef 0.72, 95% CI 0.57–
0.91, p = 0.006, Fig 4C). However, there were no significant sex-specific differences among
children whose mothers were randomized to IPTp-SP8w (coef 1.07, 95% CI 0.86–1.32,
p = 0.57, Fig 4A) or IPTp-DP8w (coef 1.09, 95% CI 0.97–1.38, p = 0.44, Fig 4B). Together,
these data suggest that consistent in utero exposure to DP may lead to sex-specific differences
in PQ metabolism in infancy, with lower PQ levels following administration among female
infants.
Discussion
In many parts of Africa, the current standard of care for IPTp—SP given at routine antenatal
visits—remains inadequate to prevent malaria in pregnancy. DP has emerged as a promising
alternative to IPTp-SP in settings with high SP resistance [7,28], but an important consider-
ation is what impact IPTp-DP has on the risk of malaria during infancy. In contrast to our
original hypothesis, we found that children born to mothers given IPTp-DP did not have a
lower risk of malaria in infancy than children born to mothers given IPTp-SP. Rather, in a set-
ting where children were given IPT with DP every 12 weeks during infancy, IPTp-DP4w was
associated with a higher risk of malaria and P. falciparum infection in infancy—but only in
female infants. Although levels of malaria-specific antibodies in cord blood did not signifi-
cantly differ between IPTp groups and/or sex, female children whose mothers were random-
ized to IPTp-DP4w had significantly lower PQ levels during infancy compared to male
children, suggesting that consistent in utero exposure to DP may lead to sex-specific differ-
ences in PQ metabolism in infancy.
Several epidemiologic and immunologic studies have previously suggested that in utero
exposure to malaria may significantly increase a child’s subsequent risk of malaria [9–14],
potentially by leading to immunologic tolerance of the parasite [11]. However, this has not
been a universal observation, with some studies finding no significant association between in
utero malaria exposure and subsequent malaria risk [16–18], and others reporting significant
effect modification by maternal gravidity [14]. Importantly, as these were all observational
studies, it is entirely possible that these associations are the result of confounding (i.e., mothers
with malaria in pregnancy may live in foci of higher malaria transmission, and, therefore, their
children are more likely to be exposed to infected mosquitoes in infancy) [19]. Although inter-
ventional studies following children born to mothers randomized to different IPTp regimens
might more causally assess this question, few such RCTs have been performed. In the 4 studies,
to our knowledge, in which pregnant women were randomized to different IPTp regimens
and children followed during infancy, and exposure to infected mosquitoes can therefore be
presumed to be equal between groups of children following birth, the incidence of malaria was
not significantly different between groups [12,18,20,21]. However, in 3 of these 4 studies, the
Fig 3. Antibody levels stratified by maternal IPTp assignment (IPTp-SP8w versus IPTp-DP4w) measured in maternal
blood at delivery (A) and infant cord blood (B). p< 0.05; p< 0.01. AMA1, Apical membrane antigen 1; CSP,
circumsporozoite protein; EBA, erythrocyte binding antigen; Etramp4, Early transcribed membrane protein 4; GEXP,
gametocyte export protein; GST, Glutathione S-transferase; H103/MSP11, merozoite surface protein 11; HSP40, Heat shock
protein 40; Hyp2, Plasmodium exported protein; IPTp, intermittent preventive treatment of malaria in pregnancy; IPTp-
DP4w, IPTp-DP every 4 weeks; IPTp-SP8w; IPTp-SP every 8 weeks; MSP1, merozoite surface protein 1; MSP2Ch150 and
MSP2Dd2, merozoite surface protein 2 of Ch150/90 and Dd2 alleles; Rh2, Reticulocyte-binding protein homologue 2; Rh4,
Reticulocyte-binding protein homologue 4; SBP1, skeleton-binding protein 1; SEA, Schizont egress antigen; TT, tetanus
toxoid.
https://doi.org/10.1371/journal.pmed.1002606.g003
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Fig 4. Mean PQ levels measured 28, 56, and 84 days posttreatment among children whose mothers were
randomized to IPTp-SP8w (A), IPTp-DP8w (B), and IPTp-DP4w (C). Marginal estimates obtained using
generalized estimating observations with log link and robust standard errors, accounting for repeated measurements in
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experimental group (IPTp-SP + LLIN, IPTp with mefloquine, or ISTp with AL) did not signifi-
cantly reduce the burden of placental malaria in comparison to controls (LLIN alone or IPTp-
SP for the latter 2 trials, respectively) [22–24]. In the older, placebo-controlled trial of IPTp
with mefloquine in Thailand, mefloquine significantly reduced the burden of malaria in preg-
nancy in comparison to placebo. However, the child’s age at first malaria episode was assessed
only through interview of the mother, and malaria blood smears were only performed at 1
week, 2 months, and 9 months of age [20].
In our placebo-controlled, randomized controlled study, IPTp-DP4w significantly reduced
the burden of malaria infection during pregnancy and at delivery, offering an ideal opportu-
nity to determine what impact reducing exposure to malaria in pregnancy might have on the
risk of malaria in infancy. Children were followed through 2 years of age with both active and
passive surveillance, allowing for precise determination of malaria metrics in infancy. Our
study differed from the previously described studies above in that children born to mothers
randomized to different IPTp interventions were themselves given IPT with DP every 12
weeks during infancy. In this setting, where the overall incidence of malaria in infancy was rel-
atively low (0.3 episodes PPY), female infants whose mothers were randomized to IPTp-DP4w
had an apparently 4-fold increased incidence of malaria and hazard of parasitemia following
receipt of DP in infancy compared to female infants whose mothers were randomized to
IPTp-SP8w. Female infants whose mothers were randomized to IPTp-DP8w also had nonsig-
nificantly increased incidence of malaria and hazard of parasitemia. Importantly, no differ-
ences were observed among male children, adding to a growing literature suggesting sex-based
differences in susceptibility to infectious diseases and vaccinations [44–47].
What might explain these sex-specific differences in malaria risk among children whose moth-
ers were given different IPTp regimens? Several potential mechanisms for sex-based differences
in susceptibility to infectious diseases have been described, including genetic differences attribut-
able to X chromosome inactivation [48], sex-dependent differences in glucocorticoid receptor
expression and fetal-placental responsivity to cortisol [49], and sex-specific differences in neona-
tal and infant immune responses [46,50]. In this study, we measured antibody levels to a broad
array of antimalarial antigens in cord blood, given prior literature suggesting that passive transfer
of protective antibodies from the mother to the newborn may mediate protection from malaria
in the first 6–12 months of life [37,43,51]. Although we did not observe significant differences in
antibody levels between IPTp groups or between females and males, our assay was limited to the
antigens screened and did not include assessment of antibody functionality.
In our setting, an increased malaria risk among children was only observed among female
infants whose mothers were randomized to IPTp with DP4w. Furthermore, we observed lower
PQ concentrations among female infants whose mothers were randomized to IPTp with
DP4w. Although pharmacokinetic studies of DP have not observed sex-specific differences in
PQ levels to date, one possible explanation for these findings is that PQ exposure in utero or as
a neonate may result in clinically important, sex-specific differences in PQ metabolism. PQ
has been found in breast milk [52], and although transplacental transfer has not been docu-
mented for PQ, related aminoquinolones chloroquine [53] and mefloquine [54] are known to
cross the placenta. PQ is metabolized by cytochrome P450 (CYP) 3A4/2C8 in adults [55], but
enzymes responsible for PQ metabolism in infancy are not known. During the first 2 years of
life, fetal CYP3A7 is gradually replaced by CYP3A4 [56], and potential explanations for sex-
children. p< 0.05. p< 0.01. DP, dihydroartemisinin-piperaquine; IPTp, intermittent preventive treatment of
malaria in pregnancy; DP4w, IPTp-DP given every 4 weeks; DP8w, IPTp-DP given every 8 weeks; SP8w, IPTp-SP
given every 8 weeks; PQ, piperaquine; SP, sulfadoxine-pyrimethamine.
https://doi.org/10.1371/journal.pmed.1002606.g004
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specific differences in PQ metabolism include sex-specific induction of fetal hepatic enzymes
such as CYP3A7, which has been observed among female fetuses exposed to smoke [57], or
accelerated maturation of adult CYP3A4, which may preferentially affect females who may
have higher concentrations of CYP3A4 [58]. Further study will be needed to characterize the
etiology of the lower PQ concentrations identified in female infants with mothers who received
more frequent DP dosing.
Although we report findings from a randomized clinical trial, there were several important
limitations. Our results suggesting an increased risk of malaria in female infants whose moth-
ers were randomized to IPTp-DP must be interpreted with caution, as small sample size (espe-
cially when stratified by infant sex) may lend to spurious results. Furthermore, as children in
this study all received DP every 12 weeks in infancy, we are unable to determine what impact
maternal IPTp-DP has on infants who do not receive any IPT in infancy, which may be a more
generalizable population across Africa. We are currently conducting a larger study comparing
IPTp-DP with IPTp-SP among 782 mother-child pairs, in which children will be followed for
1 year following birth and not receive IPT in infancy. Finally, although suggestive of a potential
mechanism of increased risk, our PQ data are speculative and require more formal pharmaco-
kinetic/pharmacodynamic modelling, which is in progress.
In conclusion, our results show that effective prevention of in utero exposure to malaria
with IPTp-DP does not result in a reduced risk of malaria in infants in comparison to IPT-SP.
In contrast, in a setting where children were given IPT with DP every 12 weeks during infancy,
IPTp-DP was associated with an increased risk of malaria in infancy, but only in female chil-
dren. Future studies are needed to better understand the biological mechanisms of in utero
drug exposure on drug metabolism and how this may affect the dosing of antimalarial drugs
for treatment and prevention during infancy.
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